Impact of body mass index on survival in women receiving chemotherapy for early breast cancer

Purpose The impact of elevated body mass index (BMI) on overall survival (OS) in patients receiving modern anthracycline-taxane chemotherapy for early breast cancer (EBC) has not yet been well established. The purpose of our study was to examine overall survival (OS) by BMI category in women with EB...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2022-11, Vol.196 (2), p.329-339
Hauptverfasser:	Pezo, Rossanna C., Chan, Kelvin K. W., Mata, Danilo Giffoni M. M., Menjak, Ines, Eisen, Andrea, Trudeau, Maureen
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Analysis Anthracycline Anthracyclines Body mass index Body weight Breast cancer Cancer Cancer research Chemotherapy Clinical Trial Cyclophosphamide Doxorubicin Epirubicin ErbB-2 protein Medicine Medicine & Public Health Oncology Oncology, Experimental Operating systems Overweight Paclitaxel Statistical analysis Survival Taxanes Underweight World health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Purpose The impact of elevated body mass index (BMI) on overall survival (OS) in patients receiving modern anthracycline-taxane chemotherapy for early breast cancer (EBC) has not yet been well established. The purpose of our study was to examine overall survival (OS) by BMI category in women with EBC receiving either doxorubicin (A), cyclophosphamide (C) + paclitaxel (P) or fluorouracil (F), epirubicin (E), cyclophosphamide (C) + docetaxel (D). Methods This was a retrospective cohort study in patients ≥ 18 years with resected stage I–III BC diagnosed between 2007 and 2017 in Ontario, identified through linkage of administrative databases. Patients were classified according to baseline BMI into underweight (
ISSN:	0167-6806 1573-7217
DOI:	10.1007/s10549-022-06744-8